Study 24 of 31Retatrutide (LY3437943) literatureBMJ (Clinical research ed.)Top journal2026
Retatrutide trial: Triple action jab can cause weight loss of up to 25%, results suggest.
Not reported in abstract.
Where it sits
this study against the rest of the retatrutide (ly3437943) corpus13
Preclinical · this one
7
Observational
0
Open-label
5
Randomised
6
Reviews
Summary and findings
Not reported in abstract.
How much of this paper we could read: title only (0.10). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
2026
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Key findings
- Not reported in abstract.
- Not reported in abstract.
- Not reported in abstract.
Limitations
- Not reported in abstract.
- Not reported in abstract.
- Not reported in abstract.
Elsewhere in the Retatrutide (LY3437943) corpus
DUnapproved GLP-1 Drugs Retatrutide and Zenagamtide Sold Online Are No Bargain.JAMA · 2026—DRetatrutide in adults with obesity and type 2 diabetes: what have we learned from TRIUMPH-2?Lancet (London, England) · 2026—DRetatrutide trial: Triple action jab can cause weight loss of up to 25%, results suggest.BMJ (Clinical research ed.) · 2026—AThe First Triple Agonist for Antiobesity: Retatrutide.Cardiology in review · 2024 · Not reported in abstract.reviewDThe First Triple Agonist for Antiobesity: Retatrutide.Cardiology in review · 2026 · Not reported in abstract.reviewARetatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.Lancet (London, England) · 2026 · -18.8% bodyweight change at week 80 with retatrutide 12 mg, n=287, p<0.0001.Human